Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization

Archives of Ophthalmology

Volumn 114, Issue 8, 1996, Pages 978-985

  Husain, Deeba ^a   Miller, Joan W ^a   Michaud, Norman ^b   Connolly, Edward ^a   Flotte, Thomas J ^b   Gragoudas, Evangelos S ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOROID CAPILLARY LAYER; CONTROLLED STUDY; ELECTRON MICROSCOPY; EYE FUNDUS; EYE PHOTOGRAPHY; FLUORESCENCE ANGIOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LASER; MONKEY; NONHUMAN; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION;

EID: 0029741184     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1996.01100140186012     Document Type: Article

References (35)

1. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
2. Ferris FL III, Fine S, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
3. Hyman LG, Lilienfeld AM, Ferris FL III, Fine SL. Senile macular degeneration: a case control study. Am J Epidemiol. 1983;118:213-227.
4. Goldberg J, Flowerdew G, Smith E, Smith E, Brody J, Tso M. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol. 1988;128: 700-710.
5. The Eye Disease Case-Control Group. Risk factor for neovascular age-related macular degeneration. Arch Ophthalmol. 1992;110:1701-1708.
6. Bressler NM, Bressler SB, West SK, et al. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol. 1989;107: 847-852.
7. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205-210.
8. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol. 1986;104:694-701.
9. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol. 1986;104:503-512.
10. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol. 1994;112:489-499.
11. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesion in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1219-1230.
12. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal lesions of age-related degeneration: updated findings from two clinical trials. Arch Ophthalmol. 1993;111:1200-1209.
13. Bressler NM, Bressler SB, Gragoudas ES. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol. 1987;105:209-213.
14. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810-818.
15. Kramer M, Miller JW, Michaud N, et al. Liposomal BPD verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427-438.
16. Manyak MJ, Russo A, Smith PD, Glatstein E. Photodynamic therapy. J Clin Oncol. 1988;6:380-391.
17. Gomer C. Photodynamic therapy in the treatment of malignancies. Semin Hematol. 1989;26:27-31.
18. Dougherty T, Potter W, Belinier D. Photodynamic therapy for the treatment of cancer: current status and advances. In: Kessel D, ed. Photodynamic Therapy of Neoplastic Disease. Boca Raton, Fla: CRC Press Inc; 1990:1-20.
19. Marcus S. Photodynamic therapy of human cancer: clinical status, potentials and needs. In: Gormer C, ed. Future Directions and Applications in Photodynamic Therapy. Bellingham, Wash: Society of Photo-Optical Instrumentation Engineers; 1990;IS6:5-56.
20. Zhou C. New trends in photobiology: mechanisms of tumor necrosis induced by pholodynamic therapy. J Photochem Photobiol B. 1989;63:87-93.
21. Aveline B, Hasan T, Raymond R. Photophysical and photosensitizing properties of BPD-MA. Photochem Photobiol. 1994;59:328-335.
22. Jori G, Reddi E, Cozzani I, Tomio L. Controlled targeting of different subcellular sites by porphyrins in tumor-bearing mice. Br J Cancer. 1986;53:615-621.
23. Richter A, Waterfield E, Jain A, et al. Photosensitizing potency of structural analogs of benzoporphyrin derivative (BPD-MA) in a mouse model. Br J Cancer. 1991;63:87-93.
24. Spikes J, Straight R. Sensitized photochemical process in biological systems. Annu Rev Phys Chem. 1967;18:409.
25. Lui J. Hruza L, Kollias N, et al. Photodynamic therapy of malignant skin tumors with benzoporphyrin derivative monoacid ring A (BPD-MA): preliminary investigations. In: Proceedings of Lasers in Otolaryngology, Dermatology, and Tissue Welding. Bellingham, Wash: Society of Photo-Optical Instrumentation Engineers; 1993;1876:147-151.
26. Richter A, Waterfield E, Jain AK, et al. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD-MA) to tumor tissue in a mouse tumor model. Photochem Photobiol. 1993;57:1000-1006.
27. Schmidt-Erfurth U, Bauman W, Gragoudas ES, et al. Photodynamic therapy of experimental cnoroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology. 1994;101:89-99.
28. Jamieson C, McDonald W, Levy J. Preferential uptake of benzoporphin derivative by leukemic vs normal cells. Leuk Res. 1990;14:209-219.
29. Embree L, Gelmon KA, Lohr A, et al. Chromatographic analysis and pharmokinetics of liposomal encapsulated doxorubicin in non-small cell lung cancer patients. J Pharm Sci. 1993;82:627-634.
30. Ranade W. Drug delivery systems, I: site-specific drug delivery using liposomes as carriers. J Clin Pharmacol. 1989;29:685-694.
31. Hruza L, Lui H, Kollias N, et al. Photodynamic therapy of psoriasis: preliminary evaluation of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol. 1993;(suppl)57:50S.
32. Ohkuma H, Ryan SJ. Experimental subretinal neovascularization in the monkey. Arch Ophthalmol, 1982;101:1102-1110.
33. Ryan SJ. Subretinal neovascularization: natural history of an experimental model. Arch Ophthalmol. 1982;100:1804-1809.
34. Kramer M, Kenney AG, Delori F, et al. Imaging of experimental choroidal neovascularization (CNV) using liposomal benzoporphyrin derivative monoacid (BPD-MA) angiography. Invest Ophthalmol Vis Sci. 1995;36(suppl 4):236. Abstract.
35. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular lesions of age-related macular degeneration: five-year results from randomized clinical trials. Arch Ophthatmol. 1991;109:1109-1114.